Aysegul Tokatli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8527972/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Key features and clinical variability of COG6-CDG. Molecular Genetics and Metabolism, 2015, 116, 163-170.	1.1	49
2	Hereditary Dopamine Transporter Deficiency Syndrome: Challenges in Diagnosis and Treatment. Neuropediatrics, 2017, 48, 049-052.	0.6	28
3	Lack of prolidase causes a bone phenotype both in human and in mouse. Bone, 2015, 72, 53-64.	2.9	23
4	Genotypicâ€phenotypic features and enzyme replacement therapy outcome in patients with mucopolysaccharidosis VI from Turkey. American Journal of Medical Genetics, Part A, 2017, 173, 2954-2967.	1.2	17
5	Molecular analysis of 16 Turkish families with DHPR deficiency using denaturing gradient gel electrophoresis (DGCE). Human Genetics, 2000, 107, 546-553.	3.8	16
6	Phenotypic and genotypic spectrum of Turkish patients with isovaleric acidemia. European Journal of Medical Genetics, 2014, 57, 596-601.	1.3	15
7	Post-mortem detection of FLAD1 mutations in 2 Turkish siblings with hypotonia in early infancy. Neuromuscular Disorders, 2018, 28, 787-790.	0.6	14
8	High prevalence of cerebral venous sinus thrombosis (CVST) as presentation of cystathionine beta-synthase deficiency in childhood: Molecular and clinical findings of Turkish probands. Gene, 2014, 534, 197-203.	2.2	13
9	Evaluation and identification of IDUA gene mutations in Turkishpatients with mucopolysaccharidosis type I. Turkish Journal of Medical Sciences, 2016, 46, 404-408.	0.9	11
10	Genotypes and estimated prevalence of phosphomannomutase 2 deficiency in Turkey differ significantly from those in Europe. American Journal of Medical Genetics, Part A, 2020, 182, 705-712.	1.2	10
11	Acetaminophen-induced hepatotoxicity in a glutathione synthetase-deficient patient. Turkish Journal of Pediatrics, 2007, 49, 75-6.	0.6	10
12	The effectiveness of enzyme replacement therapy on cardiac findings in patients with mucopolysaccharidosis. Journal of Pediatric Endocrinology and Metabolism, 2019, 32, 1049-1053.	0.9	9
13	Oral health status of children with phenylketonuria. Journal of Pediatric Endocrinology and Metabolism, 2020, 33, 361-365.	0.9	8
14	DNACJ12 deficiency in patients with unexplained hyperphenylalaninemia: two new patients and a novel variant. Metabolic Brain Disease, 2021, 36, 1405-1410.	2.9	8
15	Predictors of acute metabolic decompensation in children with maple syrup urine disease at the emergency department. European Journal of Pediatrics, 2020, 179, 1107-1114.	2.7	4
16	Partial hydatidiform mole in a phenylketonuria patient treated with sapropterin dihydrochloride. Gynecological Endocrinology, 2017, 33, 19-20.	1.7	3
17	Retrospective evaluation of 85 patients with urea cycle disorders: one center experience, three new mutations. Journal of Pediatric Endocrinology and Metabolism, 2020, 33, 721-728.	0.9	3
18	Comment on: "Multiple acyl‑CoA dehydrogenase deficiency in elderly carriersâ€: Journal of Neurology, 2020, 267, 1209-1210.	3.6	1

#	Article	IF	CITATIONS
19	Oral health status of children and young adults with maple syrup urine disease in Turkey. BMC Oral Health, 2021, 21, 8.	2.3	1
20	Sensory, voluntary, and motor postural control in children and adolescents with mucopolysaccharidosis. Journal of Pediatric Endocrinology and Metabolism, 2021, 34, 583-589.	0.9	0
21	Evaluation of Cardiac Findings in Mucopolysaccharidosis Type III Patients. Journal of Pediatric Research, 2021, 8, 195-201.	0.2	Ο